EUCTR2019-003334-16-BG进行中（未招募）1 期
Randomised, double-blind, placebo-controlled, multicentre study to compare the efficacy and safety of novel 4 mg budesonide suppository in combination with oral mesalazine versus oral mesalazine monotherapy in patients with acute ulcerative colitis
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 360
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Signed informed consent,
- •Man or woman between 18 and 75 years of age,
- •Acute ulcerative colitis,
- •New diagnosis or established disease,
- •diagnosis confirmed by total colonoscopy and biopsy
- •Mildly to moderately active ulcerative colitis (3 < modified UC-DAI < 11), with rectal bleeding subscore of = 1, and endoscopic subscore of = 2 at the most active site in the segment of the rectum
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 282
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 78
排除标准
- •Crohn’s disease, indeterminate colitis, ischemic colitis, diverticular disease-associated colitis, microscopic colitis
- •Presence of colitis of a different origin (e.g. infectious or parasitic, drug-induced),
- •Previous colonic surgery (except appendectomy, haemorrhoidectomy, and endoscopic removal of polyps),
- •Abnormal laboratory values, presence of or suspected concomitant disease(s) that could affect study-specific assessments and/or their evaluation, or might compromise patients' safety and/or compliance (e.g. organic diseases or infections of the gastrointestinal tract (with exceptions), certain malignancies or cancers, certain metabolic disorders)
- •Regular oral treatment with more than 2.4 g/d mesalazine (or therapeutic equivalent, i.e., either > 2.4 g/d olsalazine, > 5.6 g/d balsalazide, or > 6.2 g/d sulfasalazine) within the last 4 weeks prior to baseline,
- •Regular rectal treatment with more than 0.5 g/d mesalazine, olsalazine or more than 1 g/d sulfasalazine within the last 4 weeks prior to baseline,
- •Oral/rectal/intravenous corticosteroids therapy within the last 4 weeks priorto screening endoscopy,
- •For Germany only: diagnosis of active COVID-19
研究者
相似试验
进行中（未招募）
1 期
Randomised, double-blind, placebo-controlled, multi-centre trial on the efficacy and safety of budesonide for induction of remission in incomplete microscopic colitis - Budesonide for induction of remission in incomplete microscopic colitisEUCTR2013-001912-31-PTDr. Falk Pharma GmbH44
进行中（未招募）
不适用
Randomised, double-blind, placebo-controlled, multi-centre trial on the efficacy and safety of budesonide for induction of remission in incomplete microscopic colitisPatients with active incomplete microscopic colitisMedDRA version: 14.1Level: PTClassification code 10056979Term: Colitis microscopicSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2013-001912-31-ESDr. Falk Pharma GmbH106
进行中（未招募）
不适用
Randomised, double-blind, placebo-controlled, multinational, multi-centre, Phase IIb / III study of the efficacy and safety of three doses of sublingual immunotherapy (SLIT) administered as tablets once daily to patients suffering from grass pollen rhinoconjunctivitisGrass Pollen Related Allergic RhinoconjunctivitisMedDRA version: 7.0Level: PTClassification code 10010744EUCTR2004-001910-15-ATStallergenes S.A.600
进行中（未招募）
1 期
Randomised, double-blind, placebo-controlled, multi-centre trial on the efficacy and safety of budesonide for induction of remission in incomplete microscopic colitisEUCTR2013-001912-31-DKDr. Falk Pharma GmbH106
进行中（未招募）
不适用
Randomised, double-blind, placebo-controlled, multinational, multi-centre, Phase IIb / III study of the efficacy and safety of three doses of sublingual immunotherapy (SLIT) administered as tablets once daily to patients suffering from grass pollen rhinoconjunctivitisGrass Pollen Related Allergic RhinoconjunctivitisMedDRA version: 7.0Level: PTClassification code 10010744EUCTR2004-001910-15-DKStallergenes S.A.600